Adial Pharmaceuticals Inc Dossier - Source-backed chat

Adial Pharmaceuticals Inc

ADILNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.19

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $4.01Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $11.8M

Enterprise Value $5.9M

Shares Outstanding 3.3M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Adial Pharmaceuticals has undergone a transformative strategic pivot from a pure-play addiction therapeutics developer to an inflammatory bowel disease (IBD) innovator through its June 2026 acquisition of Azora Therapeutics. This transaction brings AT177, a promising colon-targeted aryl hydrocarbon receptor (AhR) agonist for ulcerative colitis, into the lead pipeline position. Crucially, the acquisition is backed by an up to $64 million PIPE financing commitment, with the first $32 million tranche closed on June 12, 2026. This capital injection resolves Adial's historical going-concern and cash runway constraints, providing a robust balance sheet to advance AT177 through key Phase 1 clinical milestones. Meanwhile, its legacy asset AD04 for Alcohol Use Disorder (AUD) remains a high-potential option value, benefiting from favorable FDA policy shifts toward single-pivotal-trial approvals and a completed demonstration manufacturing batch.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.00

Mean target$7.00

High · most bullish analyst$8.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5020%

AT177 encounters unexpected toxicological or formulation hurdles during IND-enabling studies, delaying Phase 1 initiation beyond 2027 and stalling access to the second $32 million PIPE tranche. Legacy asset AD04 fails to secure a partner, and the company is forced to seek highly dilutive alternative financing to sustain operations.

Base CaseCentral scenario

$6.0050%

Adial successfully advances AT177 through IND-enabling work, leading to Phase 1 clinical trial initiation in mid-2027 and unlocking the remaining $32 million in milestone-based PIPE funding. Legacy asset AD04 continues to seek strategic partners or non-dilutive development pathways, while the company's primary valuation is driven by clinical progress in the high-value ulcerative colitis market.

Bull CaseUpside scenario

$8.0030%

AT177 successfully completes IND-enabling studies and initiates Phase 1 trials ahead of schedule in early 2027, unlocking the second $32 million PIPE tranche. Clinical data demonstrates best-in-class efficacy in ulcerative colitis with zero systemic immunosuppressive side effects, attracting a major pharmaceutical licensing partner. Concurrently, Adial secures a strategic partnership or non-dilutive funding to advance AD04 under a single Phase 3 trial design aligned with the FDA.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Secured up to $64 million in PIPE financing (with $32 million closed upfront), resolving historical cash runway issues and funding AT177 through Phase 1 clinical milestones.
Strategic pivot into the lucrative ulcerative colitis market with AT177, a colon-targeted AhR agonist designed to avoid systemic safety risks.
Strong institutional backing from specialized biotech investors including Coastlands Capital, Kern Capital, Boxer Capital, and Stonepine Capital.
Valuable option-value in legacy asset AD04, which has completed Phase 3 demonstration batch manufacturing and stands to benefit from a modernized, single-pivotal-trial FDA approval pathway.

Key Investment Risks

Clinical-stage execution risk: AT177 is currently in pre-clinical IND-enabling stages, with Phase 1 trials not expected to begin until mid-2027.
Milestone dependency: Access to the second $32 million tranche of the PIPE financing is strictly contingent on initiating the Phase 1 clinical study.
Stockholder approval risk: The full conversion of preferred shares issued to Azora holders and certain warrant mechanics require upcoming stockholder approval.
Legacy asset uncertainty: AD04 development remains paused or slow-moving pending a strategic partnership or additional non-dilutive funding.

Thesis Invalidation Triggers

Failure to initiate the Phase 1 clinical trial for AT177 by late 2027, preventing the closing of the second $32 million financing tranche.
Unfavorable pre-clinical safety or toxicology signals from AT177 IND-enabling studies.
Rejection of the Azora transaction share conversion or warrant terms by Adial stockholders.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.